Quantitative systems pharmacology model for Alzheimer’s disease to predict the effect of aducanumab...
Quantitative systems pharmacology model for Alzheimer’s disease to predict the effect of aducanumab on brain amyloid
About this item
Full title
Author / Creator
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Alzheimer's disease (AD) is an irreversible, progressive brain disorder that impairs memory and cognitive function. Dysregulation of the amyloid‐β (Aβ) pathway and amyloid plaque accumulation in the brain are hallmarks of AD. Aducanumab is a human, immunoglobulin gamma 1 monoclonal antibody targeting aggregated forms of Aβ. In phase Ib and phase II...
Alternative Titles
Full title
Quantitative systems pharmacology model for Alzheimer’s disease to predict the effect of aducanumab on brain amyloid
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_7f7bb9c94560451a90a1143017ac5a1c
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_7f7bb9c94560451a90a1143017ac5a1c
Other Identifiers
ISSN
2163-8306
E-ISSN
2163-8306
DOI
10.1002/psp4.12759
